Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21537525 | 1.00 | CTSL (0.35) | CTSLCTSBCTSKJAK2JAK1 | |
| SCHEMBL8263000 | 1.00 | CTSL (0.35) | CTSLCTSBCTSKJAK2JAK1 | |
| SCHEMBL20664323 | 0.93 | HCRTR2 (0.33) | CTSLCTSBCTSKJAK2JAK1 | |
| SCHEMBL11957389 | 0.93 | HCRTR2 (0.33) | CTSLCTSBCTSKJAK2JAK1 | |
| SCHEMBL803142 | 0.93 | HCRTR2 (0.33) | CTSLCTSBCTSKJAK2JAK1 | |
| SCHEMBL14701093 | 0.93 | HCRTR2 (0.33) | CTSLCTSBCTSKJAK2JAK1 | |
| SCHEMBL20664231 | 0.91 | HCRTR2 (0.32) | CTSLCTSBCTSKJAK2JAK1 | |
| SCHEMBL20664361 | 0.88 | HCRTR2 (0.31) | CTSLCTSBCTSKJAK2JAK1 | |
| SCHEMBL11266221 | 0.88 | HCRTR2 (0.31) | CTSLCTSBCTSKJAK2JAK1 | |
| SCHEMBL11266225 | 0.88 | HCRTR2 (0.31) | CTSLCTSBCTSKJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160355511-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2016-12-08 | — | — | US | disclosed |
| US-20160355511-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2016-12-08 | — | — | US | disclosed |
| US-9309221-B2 | 1-substituted indazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-9309221-B2 | 1-substituted indazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-9051295-B2 | 1-substituted indazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051295-B2 | 1-substituted indazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-06-09 | — | — | US | disclosed |
| EP-2837623-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-02-18 | — | — | EP | disclosed |
| US-20150031681-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150031681-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8765786-B2 | 1-substituted indazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765786-B2 | 1-substituted indazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140121244-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121244-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121243-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121243-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| WO-2013154109-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2013-10-17 | — | — | WO | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121244-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | CHRNA3, CHRNB3, CHRNA7 | CTSL 4351/4885CTSB 3336/4885CTSK 3850/4885 |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | GSK3A, CDK11A, CDK1 | CTSL 3807/4885CTSB 4266/4885CTSK 3631/4885 |
| US-20160355511-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | CHRNA3, CHRNB3, CHRNA7 | CTSL 4351/4885CTSB 3336/4885CTSK 3850/4885 |
| US-20140121243-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | CHRNA3, CHRNB3, CHRNA7 | CTSL 4351/4885CTSB 3336/4885CTSK 3850/4885 |
| US-20150031681-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | CHRNA3, CHRNB3, CHRNA7 | CTSL 4351/4885CTSB 3336/4885CTSK 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.